Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Provectus Pharmaceuticals has received allowance of its patent application in the EU covering its lead dermatology agent, PH-10, along with a number of related agents and their use.
Subscribe to our email newsletter
PH-10 is currently undergoing Phase II clinical testing in New York City for the treatment of moderate to severe psoriasis, and Provectus expects to commence Phase II testing in another indication within the next few months.
Provectus has also received allowance of another patent application in Canada covering applicator devices used with PH-10 and related agents. The pending patents cover topical products for treatment of skin diseases such as psoriasis and eczema, along with certain medical devices for application of PH-10 to internal surfaces of the body.
Craig Dees, CEO of Provectus, said: “The EPO patent will also cover topical products based on PH-12, our novel photoactive analog of PH-10. As we increase the pace of our clinical trials for both PH-10 and our lead oncology agent PV-10, we believe that aggressively protecting our intellectual assets will be vital to our eventual marketing success.”